NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

68Ga-BCMA PET/CT in Multiple Myeloma

NCT07319897

RecruitingPhase 2, Phase 3

Sponsor: Peking University First Hospital

Conditions: Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm

Interventions: 68Ga-BCMA PET/CT

Countries: China

This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography/computed tomography (PET/CT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.

Eligibility overview

Sex: ALL

Age: 18 Years to 80 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* patients with suspected or previously diagnosed multiple myeloma (MM) who were scheduled for bone marrow aspiration or tissue biopsy within two weeks, including those undergoing initial diagnostic evaluation or follow-up/re-evaluation for disease monitoring or relapse;
* patients with confirmed symptomatic MM;
* ability to understand and voluntarily sign written informed consent;
* ability to comply with study procedures;
* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

Exclusion Criteria:

* pregnancy or lactation;
* inability to comprehend study procedures or cooperate with protocol requirements;
* any other condition judged by the investigator to potentially interfere with study participation.

Locations (5)

Beijing, Beijing Municipality, China
Beijing, Beijing Municipality, China
Beijing, Beijing Municipality, China
Shijiazhuang, Hebei, China
Jilin City, Jilin, China